US5326690A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Ovarian cancer ascites factor, in isolated form
Assignee: LPL Technologies Inc
•
Filing: 1993-10-01
•
Granted: 1994-07-05
•
Expires: 2013-10-01
Abstract
Abstract Herein described is an ovarian cancer activating factor that has been isolated from ovarian cancer ascites fluid. The factor may be utilized in its isolated form in a screening program aimed at identifying inhibitors of factor-mediated ovarian cancer activation, or as a growth supplement useful for culturing ovarian and other cancer cell lines.
Inventors
- 👤 Yan Xu
- 👤 Anne E. Goodbody
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 13:33
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/13
Claims Analysis
Total Claims: 2
Claim 1
Independent Claim
92 words
A screening method useful for identifying compounds capable of inhibiting an ovarian cancer cell factor, which method comprises the steps of: (1) incubating (a) a factor which is free of proteins and peptides, which is recoverable from ovarian cancer ascites fluid, and which stimulates intracellular calcium release within ovarian cancer cells, with (b) a candidate inhibitor of said factor, and (c) a factor-responsive cell-line; and (2) determining the effect of said candidate inhibitor on the intracellular calcium levels within said factor-responsive cell-line, whereby the inhibitory effect of the candidate inhibitors is revealed.
Claim 2
Dependent Claim
92 words
A screening method useful for identifying compounds capable of inhibiting an ovarian cancer cell factor, which method comprises the steps of: (1) incubating (a) a factor which is free of proteins and peptides, which is recoverable from ovarian cancer ascites fluid, and which stimulates intracellular calcium release within ovarian cancer cells, with (b) a candidate inhibitor of said factor, and (c) a factor-responsive cell-line; and (2) determining the effect of said candidate inhibitor on the intracellular calcium levels within said factor-responsive cell-line, whereby the inhibitory effect of the candidate inhibitors is revealed.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-07-04 | 1998-01-03 | 1998-07-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-07-04 | 2002-01-03 | 2002-07-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-07-04 | 2006-01-03 | 2006-07-05 | $7700.00 | Window Closed / Lapsed |